EKF Diagnostics (EKF) Competitors

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.

Does the media refer more to EKF or CREO?

In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. Creo Medical Group's average media sentiment score of 0.28 beat EKF Diagnostics' score of -1.29 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
EKF Diagnostics	Negative
Creo Medical Group	Neutral

Which has higher valuation and earnings, EKF or CREO?

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. EKF Diagnostics is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£66.64M	1.77	-£10.10M	-£0.02	-1,300.00
Creo Medical Group	£29.27M	3.76	-£25.04M	-£0.11	-277.27

Which has more volatility and risk, EKF or CREO?

EKF Diagnostics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Creo Medical Group has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.

Is EKF or CREO more profitable?

EKF Diagnostics has a net margin of -15.16% compared to Creo Medical Group's net margin of -85.54%. EKF Diagnostics' return on equity of -11.31% beat Creo Medical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	-15.16%	-11.31%	5.23%
Creo Medical Group	-85.54%	-38.49%	-19.98%

Do analysts rate EKF or CREO?

Creo Medical Group has a consensus target price of GBX 100, suggesting a potential upside of 227.87%. Given Creo Medical Group's higher probable upside, analysts plainly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Creo Medical Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals believe in EKF or CREO?

70.2% of EKF Diagnostics shares are held by institutional investors. Comparatively, 35.3% of Creo Medical Group shares are held by institutional investors. 5.5% of EKF Diagnostics shares are held by insiders. Comparatively, 11.7% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in EKF or CREO?

EKF Diagnostics received 221 more outperform votes than Creo Medical Group when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 67.52% of users gave Creo Medical Group an outperform vote.

Company	Underperform	Outperform
EKF Diagnostics	Outperform Votes 327 76.76%	Underperform Votes 99 23.24%
Creo Medical Group	Outperform Votes 106 67.52%	Underperform Votes 51 32.48%

Summary

EKF Diagnostics beats Creo Medical Group on 10 of the 17 factors compared between the two stocks.